IL179243A0 - Modulation of immunoglobulin production and atopic disorders - Google Patents

Modulation of immunoglobulin production and atopic disorders

Info

Publication number
IL179243A0
IL179243A0 IL179243A IL17924306A IL179243A0 IL 179243 A0 IL179243 A0 IL 179243A0 IL 179243 A IL179243 A IL 179243A IL 17924306 A IL17924306 A IL 17924306A IL 179243 A0 IL179243 A0 IL 179243A0
Authority
IL
Israel
Prior art keywords
modulation
immunoglobulin production
atopic disorders
atopic
disorders
Prior art date
Application number
IL179243A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of IL179243A0 publication Critical patent/IL179243A0/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL179243A 2004-05-19 2006-11-13 Modulation of immunoglobulin production and atopic disorders IL179243A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57240704P 2004-05-19 2004-05-19
PCT/US2005/017514 WO2005112983A2 (en) 2004-05-19 2005-05-19 Modulation of immunoglobulin production and atopic disorders

Publications (1)

Publication Number Publication Date
IL179243A0 true IL179243A0 (en) 2007-03-08

Family

ID=35428852

Family Applications (1)

Application Number Title Priority Date Filing Date
IL179243A IL179243A0 (en) 2004-05-19 2006-11-13 Modulation of immunoglobulin production and atopic disorders

Country Status (15)

Country Link
US (1) US20060024268A1 (enExample)
EP (1) EP1753458A4 (enExample)
JP (1) JP2008501042A (enExample)
KR (1) KR20070014181A (enExample)
CN (1) CN1980698A (enExample)
AU (1) AU2005244942A1 (enExample)
BR (1) BRPI0510996A (enExample)
CA (1) CA2566333A1 (enExample)
EC (1) ECSP067014A (enExample)
IL (1) IL179243A0 (enExample)
MX (1) MXPA06013483A (enExample)
NO (1) NO20065487L (enExample)
RU (1) RU2006138704A (enExample)
WO (1) WO2005112983A2 (enExample)
ZA (1) ZA200609600B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057128A (en) * 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
AU2003251900B2 (en) * 2002-07-15 2008-12-18 President And Fellows Of Harvard College Methods and compositions for modulating T helper (Th) cell development and function
WO2004083249A2 (en) * 2003-03-14 2004-09-30 Wyeth Antibodies against human il-21 receptor and uses therefor
CA2518854A1 (en) * 2003-03-21 2004-10-07 Wyeth Treating immunological disorder using agonists of interleukin-21/interleukin-21 receptor
JP2007506789A (ja) * 2003-09-25 2007-03-22 ザイモジェネティクス， インコーポレイテッド Ｉｌ−２１を用いた自己免疫疾患の治療方法
EP2633866A3 (en) * 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
KR20070057789A (ko) * 2004-08-05 2007-06-07 와이어쓰 인터루킨-21 수용체 활성의 상쇄
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
CN101180315A (zh) * 2005-04-18 2008-05-14 诺和诺德公司 Il-21变体
EP1890723A2 (en) * 2005-06-06 2008-02-27 Novo Nordisk A/S Stabilised il-21 compositions
US7914574B2 (en) * 2005-08-02 2011-03-29 Reva Medical, Inc. Axially nested slide and lock expandable device
EP1960433A2 (en) * 2005-11-28 2008-08-27 Zymogenetics, Inc. Il-21 receptor antagonists
WO2007111714A2 (en) * 2005-11-28 2007-10-04 Zymogenetics, Inc. Il-21 antagonists
AU2007310777A1 (en) 2006-10-26 2008-05-02 Novo Nordisk A/S IL-21 variants
JP2010512769A (ja) * 2006-12-21 2010-04-30 ノヴォ ノルディスク アクティーゼルスカブ Ｉｌ−２１受容体との結合が変化したインターロイキン−２１変異体
EP3103813A1 (en) 2007-12-07 2016-12-14 ZymoGenetics, Inc. Anti-human il-21 monoclonal antibodies
PE20100141A1 (es) * 2008-05-23 2010-02-22 Wyeth Corp Proteina de union al receptor de interleuquina 21
BRPI0912998A2 (pt) * 2008-05-23 2015-10-13 Wyeth Llc métodos de tratamento que utilizam proteínas de ligação do receptor para a interleucina-21
EP2344180A2 (en) * 2008-09-23 2011-07-20 Wyeth LLC Methods for predicting production of activating signals by cross-linked binding proteins
WO2010119307A1 (en) * 2009-04-14 2010-10-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for stimulating antigen-specific t cell responses using accelerated co-cultured dendritic cells
ES2778053T3 (es) 2011-01-18 2020-08-07 Bioniz Llc Composiciones para modular la actividad de la citocina gamma-c
WO2015089217A2 (en) 2013-12-10 2015-06-18 Bionz, Llc Methods of developing selective peptide antagonists
US10077301B2 (en) 2013-06-27 2018-09-18 Monash University IL-21 binding proteins
AU2015367224B2 (en) 2014-12-19 2020-12-10 Monash University IL-21 antibodies
KR102654684B1 (ko) 2015-10-09 2024-04-04 바이오니즈 테라퓨틱스, 아이엔씨. 감마-ｃ-사이토카인 활성의 조정
US11709169B2 (en) * 2017-02-07 2023-07-25 National Jewish Health Lipid abnormalities and association with atopic allergic diseases
US12030936B2 (en) 2019-05-03 2024-07-09 Bioniz Therapeutics, Inc. Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US5179017A (en) * 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) * 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) * 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) * 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) * 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) * 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4510245A (en) * 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4487603A (en) * 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) * 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US5168062A (en) * 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4596556A (en) * 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4968615A (en) * 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US4737323A (en) * 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4987071A (en) * 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) * 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP0307434B2 (en) * 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US4790824A (en) * 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) * 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
WO1990013327A1 (en) * 1989-04-28 1990-11-15 Riker Laboratories, Inc. Dry powder inhalation device
US5034413A (en) * 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
US5312335A (en) * 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) * 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5399677A (en) * 1993-12-07 1995-03-21 Genetics Institute, Inc. Mutants of bone morphogenetic proteins
SE9502800D0 (sv) * 1995-08-10 1995-08-10 Astra Ab Disposable inhaler
US20030143204A1 (en) * 2001-07-27 2003-07-31 Lewis David L. Inhibition of RNA function by delivery of inhibitors to animal cells
US7189400B2 (en) * 1998-03-17 2007-03-13 Genetics Institute, Llc Methods of treatment with antagonists of MU-1
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
US20030212022A1 (en) * 2001-03-23 2003-11-13 Jean-Marie Vogel Compositions and methods for gene therapy
WO2001077171A2 (en) * 2000-04-05 2001-10-18 Zymogenetics, Inc. Soluble zalpha11 cytokine receptors
CA2312142A1 (en) * 2000-06-22 2001-12-22 An-Go-Gen Inc. Injection system for gene delivery
EP1451322B1 (en) * 2001-11-05 2009-09-30 ZymoGenetics, Inc. Il-21 antagonists
EP1572902B1 (en) * 2002-02-01 2014-06-11 Life Technologies Corporation HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
US7556944B2 (en) * 2002-05-03 2009-07-07 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for use in preparing siRNAs
ATE435303T1 (de) * 2002-08-12 2009-07-15 New England Biolabs Inc Verfahren und zusammensetzungen in verbindung mit gen-silencing
WO2004032953A1 (en) * 2002-10-11 2004-04-22 Novo Nordisk A/S Treatment of allergic conditions by use of il 21
WO2004083249A2 (en) * 2003-03-14 2004-09-30 Wyeth Antibodies against human il-21 receptor and uses therefor
CA2518854A1 (en) * 2003-03-21 2004-10-07 Wyeth Treating immunological disorder using agonists of interleukin-21/interleukin-21 receptor
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis

Also Published As

Publication number Publication date
MXPA06013483A (es) 2007-01-23
CN1980698A (zh) 2007-06-13
BRPI0510996A (pt) 2007-12-04
JP2008501042A (ja) 2008-01-17
KR20070014181A (ko) 2007-01-31
WO2005112983A2 (en) 2005-12-01
ECSP067014A (es) 2006-12-29
NO20065487L (no) 2006-12-18
US20060024268A1 (en) 2006-02-02
CA2566333A1 (en) 2005-12-01
RU2006138704A (ru) 2008-06-27
EP1753458A2 (en) 2007-02-21
EP1753458A4 (en) 2009-07-22
ZA200609600B (en) 2010-04-28
AU2005244942A1 (en) 2005-12-01
WO2005112983A3 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
IL179243A0 (en) Modulation of immunoglobulin production and atopic disorders
ZA200802828B (en) Microcapsule and method of producing same
PL1992697T3 (pl) Wytwarzanie TNFR-Fc
IL182410A0 (en) Method of formation of the shape-retentive aggregates of gel particles and their uses
WO2008030347A8 (en) Intelligent therapy recommendation algorithm and method of using the same
IL182622A (en) Heavy chain immunoglobulin or its @ fragment @ type @ vhh @ and various related aspects
SG115690A1 (en) Strained-channel transistor and methods of manufacture
IL181303A (en) METHOD FOR CREATING DIHYDROPROTRIDINONS AND NUMBER OF THESE COMPOUNDS
GB2413342B (en) Fluid production assembly and method
GB2409699B (en) Synthetic kerbs and method of installation
EP1749447A4 (en) PROCESS FOR PRODUCING YOGURT
EP1794353A4 (en) MONOCRYSTALLINE WIRE AND METHOD OF MANUFACTURING THE SAME
ZA200801156B (en) Fastening spider and method of fastening
GB2416622B (en) Process for production of electroluminescent element and electroluminescent element
SG115845A1 (en) Modulation of trip-br function and method of treating proliferative disorders
TWI347360B (en) Method of manufacturing liquid koji
PL1672161T3 (pl) Uszczelnienie do spoin oraz sposób jego wytwarzania
GB0515820D0 (en) Improved two-part microwell plates and methods of fabricating same
EP1929883A4 (en) SOYASOUS, CONTAINING 5-NUCLEOTIDE, AND METHOD FOR THE PRODUCTION THEREOF
EP1884476A4 (en) EASILY OPENING CAN AND OPENING METHOD THEREFOR
HK1096043A (en) Modulation of immunoglobulin production and atopic disorders
EP1852019A4 (en) PROCESS FOR MANUFACTURING NON-FRITTED FOAM-BEATS AND PRODUCT OBTAINED
GB0406675D0 (en) Candles and methods of manufacture thereof
SG115782A1 (en) Corrosion-resistant member and process of producing the same
EP1791779A4 (en) SURFAX AND METHODS OF MAKING